Navigation path

PANFLUVAC


Vaccines and Correlates of Protection

Efficacious Vaccine Formulation System for Prophylactic Control of Influenza Pandemics

EC contribution
: € 3 334 798
Duration
: 48 months
Starting date
: 01/01/2007
Instrument
: STREP
Keywords
: Pandemic H5N1 influenza, intranasal delivery, virosomal vaccine, lipopeptide adjuvants, dendritic cell targeting, pre-clinical to clinical evaluation strategy
Project Number
: SP5B-CT-2007-044115
Web-site
: www.panfluvac.org

Summary:

Influenza epidemics remain a burden for both human health and national economies, as witnessed by the recent advance of the pathogenic avian H5N1 influenza virus. While the numbers of human deaths in Europe has remained relatively low, the presence of such cases in Turkey demonstrates the danger posed by this virus. The avian H5N1 virus has now been detected in wild birds in numerous European countries, and the PANFLUVAC consortium is committed to creating an efficacious vaccine against this virus, to provide strong protection in a pandemic situation.

The overall aim of PANFLUVAC is to construct vaccine delivery systems for intranasal and parenteral vaccines. New H5N1 vaccines are to be based on well-established virosome technology - proven its worth for efficacious interpandemic vaccines - as well as whole virus vaccines. This will permit comparison of the intranasal virosomal vaccine with the whole virus vaccine. The vaccine potency will be enhanced by novel adjuvants targeting dendritic cells, offering both antigen-sparing potential and immunopotentiation characteristics. Both ISCOMs and lipopeptide adjuvants are already proven immunopotentiators, biosafe for humans. Certain of these have been employed with experimental influenza vaccines which allow the new H5N1 vaccines to be fast-tracked in their development. Accordingly, PANFLUVAC will generate the first H5N1 vaccine within the first 18 months of the project.

The PANFLUVAC project is also designed to facilitate rapid modification of the vaccine in the face of virus drift. Within the preclinical evaluation, the new vaccines will be tested for the degree of heterotypic cross protection they offer. PANFLUVAC offers a generic vaccine development system to provide safe and efficacious vaccines against influenza, fitting in with the European Commission's Working Paper on Community Influenza Pandemic Preparedness and Response Planning.

[+] Read More